These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12431683)

  • 21. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis.
    Heeringa P; Brouwer E; Tervaert JW; Weening JJ; Kallenberg CG
    Kidney Int; 1998 Feb; 53(2):253-63. PubMed ID: 9461083
    [No Abstract]   [Full Text] [Related]  

  • 22. Pancytopenia in ANCA associated vasculitis: response to immunosuppressive therapy.
    Letellier E; Cunningham J; Feakins RM; Hughes GR; D'Cruz DP
    Clin Exp Rheumatol; 2003; 21(3):415-6. PubMed ID: 12846080
    [No Abstract]   [Full Text] [Related]  

  • 23. Apoptosis: the central actor in the three hits that trigger anti-neutrophil cytoplasmic antibody-related systemic vasculitis.
    Esnault VL
    Nephrol Dial Transplant; 2002 Oct; 17(10):1725-8. PubMed ID: 12270975
    [No Abstract]   [Full Text] [Related]  

  • 24. The antineutrophil cytoplasmic antibody-associated vasculitides.
    Seo P; Stone JH
    Am J Med; 2004 Jul; 117(1):39-50. PubMed ID: 15210387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis.
    Almroth G; Berlin G; Andersson B; Hahn-Zoric M
    Scand J Urol Nephrol; 2009; 43(2):160-70. PubMed ID: 18979374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis.
    Koukoulaki M; Jayne DR
    Nephron Clin Pract; 2006; 102(3-4):c100-7. PubMed ID: 16286784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy?
    Flossmann O; de Groot K
    Nat Clin Pract Nephrol; 2007 May; 3(5):236-7. PubMed ID: 17457358
    [No Abstract]   [Full Text] [Related]  

  • 28. [Antineutrophil cytoplasmic antibodies and associated diseases].
    Sghiri R; Meddeb H; Bouguila J; Jarray M; Bahri F; Nouira R; Zellama D; Achour A; Essoussi AS; Harbi A; Ghedira I
    Pathol Biol (Paris); 2009 Jul; 57(5):398-402. PubMed ID: 18834675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis.
    Harper L
    Curr Opin Rheumatol; 2010 Jan; 22(1):37-42. PubMed ID: 19770660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function.
    McGregor JG; Negrete-Lopez R; Poulton CJ; Kidd JM; Katsanos SL; Goetz L; Hu Y; Nachman PH; Falk RJ; Hogan SL
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i171-81. PubMed ID: 25805747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of awareness of skin cancer among immunocompromised patients with antineutrophil cytoplasmic antibody-associated vasculitis: a questionnaire survey.
    Ali FR; Brown N; Lear JT; Helbert M; Bruce IN; Venning MC
    Br J Dermatol; 2014 Jul; 171(1):193-5. PubMed ID: 24484377
    [No Abstract]   [Full Text] [Related]  

  • 32. [Goodpasture syndrome associated with p-ANCA microscopic vasculitis: a rare entity to recognize].
    Pralong G; Fournier C; Dayer E; Meier P
    Rev Med Suisse; 2009 Jun; 5(207):1330-4. PubMed ID: 19626934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunology in clinical practice IX. Systemic vasculitis].
    Kallenberg CG; Tervaert JW
    Ned Tijdschr Geneeskd; 1998 Jan; 142(3):118-23. PubMed ID: 9557008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of anti-cyclic citrullinated peptide antibodies in antineutrophil cytoplasmic antibody-associated vasculitis.
    Tervaert JW; Damoiseaux J; Boomsma MM; Stegeman CA
    Arthritis Rheum; 2002 Mar; 46(3):849-50. PubMed ID: 11920433
    [No Abstract]   [Full Text] [Related]  

  • 35. The neutrophil in antineutrophil cytoplasmic autoantibody-associated vasculitis.
    Schreiber A; Kettritz R
    J Leukoc Biol; 2013 Oct; 94(4):623-31. PubMed ID: 23381471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-neutrophil cytoplasmic antibody (ANCA)-associated microscopic polyangiitis following a suppurative wound infection.
    Chan B; d'Intini V; Savige J
    Nephrol Dial Transplant; 2006 Oct; 21(10):2993-4. PubMed ID: 16887851
    [No Abstract]   [Full Text] [Related]  

  • 37. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
    Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Zhao MH; Chen M; Gao Y; Wang HY
    Kidney Int; 2006 Apr; 69(8):1477-81. PubMed ID: 16572106
    [No Abstract]   [Full Text] [Related]  

  • 39. [New treatments for systemic diseases].
    Bader-Meunier B; Willems M
    Arch Pediatr; 2006 Jun; 13(6):596-8. PubMed ID: 16690273
    [No Abstract]   [Full Text] [Related]  

  • 40. [ANCA vasculitis].
    Bernis C
    Nefrologia; 2003; 23(2):103-6. PubMed ID: 12778872
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.